Neovasc to Report First Quarter 2021 Financial Results on May 6, 2021
27 April 2021 - 11:05PM
via NewMediaWire -- Neovasc Inc. (NASDAQ, TSX: NVCN) will
report financial results for the first quarter ended March 31, 2021
on Thursday, May 6, 2021. Neovasc President and Chief
Executive Officer Fred Colen and Chief Financial Officer Chris
Clark will host a conference call to review the Company’s results
at 4:30 pm EST.
Interested parties may access the conference call by dialing
(866) 269-4262 or (856) 344-9208 (International) and reference
Conference ID 4739838. Participants wishing to join the call
via webcast should use the link posted on the investor relations
section of the Neovasc website
at https://www.neovasc.com/investors/.
A replay of the webcast will be available approximately 30
minutes after the conclusion of the call using the link on the
Neovasc website.
About Neovasc Inc.
Neovasc is a specialty medical device company that
develops, manufactures and markets products for the rapidly growing
cardiovascular marketplace. The Company is a leader in the
development of minimally invasive transcatheter mitral valve
replacement technologies, and minimally invasive devices for the
treatment of refractory angina. Its products include the Neovasc
Reducer™, for the treatment of refractory angina, which is not
currently commercially available in the United States (two U.S.
patients have been treated under Compassionate Use) and has been
commercially available in Europe since 2015, and Tiara™, for the
transcatheter treatment of mitral valve disease, which is currently
under clinical investigation in the United States, Canada, Israel
and Europe. For more information, visit: www.neovasc.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and applicable Canadian
securities laws that may not be based on historical fact. When used
herein, the words "expect", "anticipate", "estimate", "may",
"will", "should", "intend," "believe", and similar expressions, are
intended to identify forward-looking statements. Forward-looking
statements may involve, but are not limited to, expectations as to
the growing cardiovascular marketplace. Forward-looking statements
are based on estimates and assumptions made by the Company in light
of its experience and its perception of historical trends, current
conditions and expected future developments, as well as other
factors that the Company believes are appropriate in the
circumstances. Many factors could cause the Company's actual
results, performance or achievements to differ materially from
those expressed or implied by the forward looking statements,
including those described in the "Risk Factors" section of the
Company's Annual Report on Form 40-F and in the Management's
Discussion and Analysis for the year ended December 31, 2020
(copies of which may be obtained
at www.sedar.com or www.sec.gov). These factors
should be considered carefully, and readers should not place undue
reliance on the Company's forward-looking statements. The Company
has no intention and undertakes no obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.646.877.9641
Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Phone: +1.646.866.4012
Sean.Leous@westwicke.com
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Jul 2023 to Jul 2024